BCL2 antisense reduces prostate cancer cell survival following irradiation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 6, 2002, Pages 647-656

  Scott, Susan L ^a   Higdon, Roger ^b,c   Beckett, Laurel ^b   Shi, Xu Bao ^b   DeVere White, Ralph W ^b   Earle, John D ^b,d   Gumerlock, Paul H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Antisense; BCL2; EBRT; Prostate cancer

Indexed keywords

COMPLEMENTARY DNA; PROTEIN BCL 2;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE; CELL SURVIVAL; CLONOGENIC ASSAY; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; LINEAR ACCELERATOR; MALE; NUCLEIC ACID PROBE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

EID: 12244271019     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802320970253     Document Type: Article

References (29)

1. Kirby R. Treatment options for early prostate cancer. Urol 1998;52:948-962.
2. Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. The Prostate 1998;37:195-206.
3. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-348.
4. Hunt A, Evan G. Till Death Us Do Part. Science 2001;203:1784-1785.
5. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes & Development 1998;13:1899-1911.
6. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: Consequences for cell cycle progression and cell death. Mol Human Reproduct 1998;4:1099-1109.
7. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: On the regulation of apoptosis regulators. The FASEB Journal 1999;13:1647-1657.
8. Antonsson B, Martinou J-C. The Bcl-2 Protein Family. Exp Cell Res 2000;256:50-57.
9. Chi S-G, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: Frequently expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
10. Shi X-B, Gumerlock PH, Muenzer JT, de Vere White RW. BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. Cancer Biotherapy & Radiopharmaceut 2001;16:421-429.
11. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, deVere White RW. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urol 1998;51:346-351.
12. Scherr DS, Vaughan Jr E, Wei J, Chung M, Felsen D, Allbright R, Knudsen BS. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12-17.
13. th Edition, Lippincott Williams & Wilkins, New York 2000, p.32-35.
14. Elkind M, Han A, Volvz KW. Radiation response of mammalian cells grown in culture. Dose dependence of division delay and postirradiation growth of surviving and nonsurviving Chinese hamster cells. J Natl Cancer Inst 1963;30:705-721.
15. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: Useful concept for intercomparison of human cell survival curves. Radiat Res 1984;99:73-84.
16. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1983;195-201
17. Bache M, Pigorsch S, Dunst J, WÅrl P, Meye A, Barel F, Schmidt H, Rath FW, Taubert H. Loss of G2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. Int J Cancer 2001;96:110-117.
18. SAS Institute, Inc. SAS Version 8. Cary, NC: SAS Institute, Inc., 1999.
19. MathSoft, Inc. S-PLUS Version 6.0. Seattle, WA: Math-Soft, Inc., 2000.
20. Leith J.T. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. The Prostate 1994;24:119-124.
21. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-b1 and bcl-2 expression. Int J Cancer 1996;69:357-363.
22. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urol 1998;52:1085-1090.
23. 1 arrest by cell-substratum interactions. Cancer Res 1997;57:1151-1156.
24. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: Relevance to radiotherapy. Int J Radiation Oncol Bio. Phys 1995;33:781-796.
25. Steel GG. The case against apoptosis. Acta Oncol 2001;40:968-975.
26. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001;91:846-850.
27. Lin S-L, Chuong C-M, Ying S-Y. A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells. Biochem Biophys Res Comm. 2001;281:639-644.
28. Chi KN, Gleave ME, Klasa R, Murray N, Dryce C, Tolcher A. A phase I trial of an antisense oligonucleotide to BCL-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC). Proceed Am Soc Clin Oncol 2000;19:330a.
29. Tolcher AW, Miyake H, Gleave M. Down-regulation of BCL-2 expression by the antisense oligonucleotide G3139 enhances paclitaxel chemosensitivity in the androgen-independent prostate cancer LNCaP xenograft model. Proceed AA CR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 1999;p. 119, Abstract #583.